Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



Mitochondria-targeted artesunate conjugated cyclometalated iridium(iii) complexes as potent anti-HepG2 hepatocellular carcinoma agents

Author affiliations

Abstract

Hepatocellular carcinoma (HCC) poses a serious threat to people's health worldwide. Artesunate (ART), one of the classical antimalarial drugs, has recently been shown to exert significant cytotoxicity in various cancers, but its bioavailability is low. Cyclometalated iridium(III) complexes have emerged as a promising class of anticancer therapeutic agents. Herein, through conjugation of two of them, three novel Ir(III)–ART conjugates, [Ir(C–N)2(bpy-ART)](PF6) (bpy = 2,2′-bipyridine, C–N = 2-phenylpyridine (ppy, Ir-ART-1), 2-(2-thienyl)pyridine (thpy, Ir-ART-2), and 2-(2,4-difluorophenyl)pyridine (dfppy, Ir-ART-3)) have been synthesized, and their potential as anti-HCC agents was evaluated. We demonstrate that Ir-ART-1–3 display higher cytotoxicity against HCC cell lines than normal liver cells, and they can especially locate to mitochondria of HepG2 cells and induce a series of mitochondria-mediated apoptosis events. Moreover, Ir-ART-1–3 can regulate the cell cycle and inhibit metastasis of HepG2 cells. Finally, in vivo antitumor evaluation also demonstrates the inhibitory activity of Ir-ART-1 on tumor growth. Taken together, these Ir(III)–ART conjugates have the potential to become drug candidates for future anti-HCC treatments.

Graphical abstract: Mitochondria-targeted artesunate conjugated cyclometalated iridium(iii) complexes as potent anti-HepG2 hepatocellular carcinoma agents

Back to tab navigation

Supplementary files

Article information


Submitted
09 Mar 2020
Accepted
12 May 2020
First published
12 May 2020

Metallomics, 2020, Advance Article
Article type
Paper

Mitochondria-targeted artesunate conjugated cyclometalated iridium(III) complexes as potent anti-HepG2 hepatocellular carcinoma agents

R. Ye, W. Peng, B. Chen, N. Jiang, X. Chen, Z. Mao and R. Li, Metallomics, 2020, Advance Article , DOI: 10.1039/D0MT00060D

Social activity

Search articles by author

Spotlight

Advertisements